The United Kingdom and the United States have forged a significant trade agreement that will maintain no import taxes on UK medicine products going into the American market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has agreed to increase funding on drugs through the National Health Service (NHS). This move secures that import taxes on these crucial products will remain at nothing for a period of 36 months.
This development comes after recent statements to significantly raise tariffs on branded drug imports, with increases floated reaching 100%.
"This deal with the UK reinforces the worldwide climate for cutting-edge drugs and introduces much-needed balance to U.S.–U.K. pharmaceutical trade," a release said.
Commercial Importance
Pharmaceuticals represent one of the UK's biggest goods shipped to the America, which is easily the biggest market for leading companies like GSK and AstraZeneca.
Statistics show that in the one-year period to the end of last September, the UK shipped medicines totaling £11.1bn to the US. This value represented a significant portion of total UK exports in that period.
"This agreement safeguards work, boosts investment and sets the stage for the UK to establish itself as a international leader for medical research," a government official remarked.
Detailed UK Commitments
The pact includes several notable pledges from the British government:
- Higher Cost Ceiling: The UK will raise the price threshold at which it deems new therapies to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a goal to double total NHS spending on medicines from 0.3% of GDP to 0.6% over the next decade.
- Payback Limit: The sum pharmaceutical firms must refund to the NHS to prevent overspending will be capped at fifteen percent. Last year, refunds topped 20%.
Recent Tensions
The deal takes place against a ongoing dispute between the drug companies and the UK government over drug pricing and regulatory access.
The disagreement were exacerbated by claims that US consumers were paying significantly more for the equivalent treatments than consumers in the UK and Europe.
Recently, several large drug company projects in the UK have been paused or cancelled, while multi-billion-dollar investments have been pledged toward projects in the United States.
The Science Minister stated that the NHS had to invest a greater share on drugs, noting that its expenditure on drugs had shrunk as a share of its resources over the previous ten-year period.
